Philips eyes expanded approval for digital imaging system for cancer

Philips ($PHG) is submitting positive study results for its digital imaging system for cancer to the FDA. The data could help the company get expanded approvals for its device in the U.S.

The controlled, multicenter pivotal validation study pitted Philips' digital whole slide imaging system against traditional microscope diagnoses. Researchers found that the study met its endpoint because the imaging device could provide a diagnosis as well as a microscope.

"Proving that digital reads are not inferior to optical reads creates a foundation for a FDA submission that, if cleared, would allow for the shift to a digital operation that, in turn, may reap the additional benefits of collaboration, workflow efficiency and the use of precise tools for measurement and counting," Dr. Michael Feldman, a professor of pathology at the Hospital of the University of Pennsylvania and a leader on the study, said in a statement.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The study included 16 pathologists at four sites in the U.S. Researchers carried out 16,000 reads across 2,000 cases.

Philips’ device is already approved in the U.S. to help doctors diagnose a certain kind of breast cancer. The latest data backs a bid by the company to get the system approved for additional indications through a de novo submission.

Read more on

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.